NCT05628610View on ClinicalTrials.gov

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Esophageal Cancer
Interventions
DRUG

Tislelizumab

200mg d1, Q3W

RADIATION

Radiation

Radiotherapy dose: 5,000 c G y / 30f

DRUG

Paclitaxel

Paclitaxel: 150mg / m2 ,d1, q3w

DRUG

Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs

cisplatin, carboplatin, naidaplatin and other platinum drugs

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT05628610 - Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer | Biotech Hunter | Biotech Hunter